Creso Pharma (ASX:CPH) - Halucenex President, CEO & Founder, Bill Fleming
Halucenex President, CEO & Founder, Bill Fleming
Source: Creso Pharma
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Creso Pharma’s (CPH) Canadian-based psychedelics company Halucenex Life Sciences completes recruitment for its phase two clinical trial
  • The trial will test the efficacy of psilocybin on people with treatment-resistant Post Traumatic Stress Disorder (PTSD)
  • Halucenex will use its Lucenex branded 10 and 25 milligram synthetic psilocybin product formulation throughout the trial
  • A total of 20 patients have been recruited and consist of veterans, firefighters, psychologists, and emergency medical responders
  • Creso Pharma has ended the day steady on the market with shares closing at 3.2 cents

Creso Pharma’s (CPH) Canadian-based psychedelics company Halucenex Life Sciences has completed recruitment for its phase two clinical trial.

The trial will test the efficacy of psilocybin on people with treatment-resistant Post Traumatic Stress Disorder (PTSD). It has been designed to be single-arm and open-lab.

Halucenex will use its Lucenex branded 10 and 25 milligram synthetic psilocybin product formulation throughout the trial.

A total of 20 patients have been recruited and consist of veterans, firefighters, psychologists, and emergency medical responders, to name a few.

While everyone in the trial suffers from PTSD, they also suffer from other mental illnesses such as ADHD, depression, anger, anxiety and suicidal thoughts.

The trial will begin on October 12 and is expected to be completed by December 14.

“Halucenex will now begin preparing its relevant treatment facilities for first dosages, which will be administered within the next two weeks,” Halucenex Founder and CEO Bill Fleming said.

Clinical trial participants will be closely monitored closely and in line with all Health Canada regulations,” Mr Fleming added.

“We look forward to providing additional updates as the trial commences, initial dosages are administered and ultimately, interim results that will highlight how synthetic psilocybin can be used to treat such a debilitating condition.”

Creso Pharma was steady on the market with shares trading at 3.2 cents at market close.

CPH by the numbers
More From The Market Online
The Market Online Video

Market Close: Autumn’s ASX200 record breaking start

The ASX200 has closed the first day of Autumn at a new record 7745.6 points -…
The Market Online Video

Ark Mines (ASX:AHK) improves REE grades at Sandy Mitchell

North Queensland-based REE explorer Ark Mines (ASX:AHK) has proven higher-grade mineralisation is present on-site.

Week 9 Wrap-up: ASX hits 2 new ATHs on US inflation + the headlines that mattered

What a week. As US markets continue to go crazy after the American earnings season (read: NVIDIA), the ASX has done the same. 
OBM

Ora Banda Mining secures $30 M placement, marks progress toward second underground mine

Ora Banda Mining (ASX:OBM) has completed a single tranche placement, securing commitments at an issue price…